Both Danish sites now open in the Screening Study of prostate cancer patients for OV’s Irofulven
Hoersholm, Denmark, September 8th, 2016 – Oncology Venture Sweden AB (OV:ST) today announced that both Danish University Hospital sites are now open for inclusion and the first patients have given consent to partake in the screening study for the Phase 2 study of Irofulven in castration-resistant prostate cancer.For the site at Skaane University Hospital in Lund, Sweden Oncology Venture has received approval from the Swedish Ethics Committee and the Regional biobankcentrum to send patients tissue for Drug Response Prediction screening in Denmark as required and will soon open this last site.